DARA BioSciences Closes at Market Private Placement Transaction
01 mars 2010 09h15 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., March 1, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc.® (Nasdaq:DARA), a biopharmaceutical development company, today announced that on February 26, 2010 it closed a private...
DARA BioSciences to Present Results of a Clinical Study for KRN5500 at the "Annual Targeting Pain with Novel Therapeutics" Meeting Sponsored by Cambridge Healthtech Institute
22 févr. 2010 10h22 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Feb. 22, 2010 (GLOBE NEWSWIRE) -- Today DARA BioSciences, Inc. (Nasdaq:DARA) announced that the results of its Phase 2 study has been identified by Cambridge Healthtech Institute...
DARA BioSciences to Present at Sidoti & Company 2010 Micro Cap Conference and OneMedForum 2010 Emerging Company Finance Conference
05 janv. 2010 13h33 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Jan. 5, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that Richard A. Franco, R.Ph., Chief Executive Officer and President, is scheduled to present at...
DARA BioSciences Reports on SurgiVision's Filing of a Registration Statement With the Securities and Exchange Commission for an Initial Public Offering (IPO)
23 déc. 2009 11h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Dec. 23, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), announced today that SurgiVision, Inc., a privately held company of which DARA owns approximately 2,200,000...
DARA BioSciences Presented Results of Its Phase 2 Study for KRN5500 at the "12th International Conference on the Mechanisms and Treatment of Neuropathic Pain"
23 nov. 2009 15h42 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Nov. 23, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a biopharmaceutical development company, presented clinical data results for KRN5500, its lead compound for...
DARA BioSciences Presented Promising Preclinical Type 2 Diabetes Study Results at the Cambridge Healthtech Institute's Conference, "Targeting Diabetes with Novel Therapeutics"
10 nov. 2009 08h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Nov. 10, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a biopharmaceutical development company, presented preclinical data for DB959, its lead compound for Type 2...
DARA BioSciences Secures Additional Intellectual Property Relating to Spicamycin (Including KRN5500)
04 nov. 2009 08h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Nov. 4, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) today announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (PTO) for U.S....
DARA BioSciences Regains NASDAQ Compliance
22 oct. 2009 08h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Oct. 22, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a development-stage biopharmaceutical company, today announced that it has received notification from The NASDAQ...
DARA BioSciences Signs Definitive Agreement to Raise Approximately $750,000 in Registered Direct Offering
13 oct. 2009 09h27 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Oct. 13, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a development-stage biopharmaceutical company, today announced that it has entered into a definitive agreement...
DARA BioSciences and America Stem Cell Broaden Collaboration
12 oct. 2009 16h45 HE
|
DARA BioSciences, Inc.
RALEIGH, N.C., Oct. 12, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a development-stage biopharmaceutical company, announced today that the Company has entered into an Addendum and...